Featured Research Search Results
Research Study on the Genetics of Breast Cancer
Clinicaltrials.gov identifier:
NCT06773897
Surveys, Registries, Interviews
A registry for anyone aged 18 and older who lives in the United States
Multi-Cancer Detection Blood Tests in Adults Without Cancer: Vanguard Study
Clinicaltrials.gov identifier:
NCT06995898
Prevention
A study testing two multi-cancer detection blood tests in people who do not have cancer
Evaluating the Safety of Nipple Sparing Mastectomy in Women With a High Risk for Breast Cancer
Clinicaltrials.gov identifier:
NCT06888388
Prevention
Study for people considering double mastectomy to reduce breast cancer risk
Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)
Clinicaltrials.gov identifier:
NCT05059444
Treatment
Post-treatment study to monitor for recurrence
An Early Detection and Prevention Study for People with an Increased Risk of Cancer (InAdvance)
Clinicaltrials.gov identifier:
NCT05463796
Prevention
Study for people at risk of cancer, including previvors, survivors and family members
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
Clinicaltrials.gov identifier:
NCT06195306
Prevention
Phase 2 study for overweight postmenopausal women at increased risk for breast cancer
Comparing a New Drug, Palazestrant, to Standard Treatment for Advanced Breast Cancer
Clinicaltrials.gov identifier:
NCT06016738
Treatment
Phase 3 study for ER-positive, HER2-negative advanced or metastatic breast cancer
Comparing Hormone Therapy With and Without Chemotherapy for Premenopausal Breast Cancer (OFSET)
Clinicaltrials.gov identifier:
NCT05879926
Treatment
Phase 3 study for premenopausal, early-stage, ER positive, HER2-negative breast cancer
Treating Advanced Breast or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)
Clinicaltrials.gov identifier:
NCT05372640
Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors
Study of a New Targeted Therapy Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer
Clinicaltrials.gov identifier:
NCT06841354
Treatment
Phase 3 treatment study for people with metastatic, triple-negative breast cancer
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT05932862
Treatment
Treatment study for people with advanced solid tumors
Using a PARP Inhibitor and Oral Chemotherapy to Treat Advanced Solid Tumors with a Mutation in BRCA1, BRCA2, PALB2, ATM or CHEK2
Clinicaltrials.gov identifier:
NCT06177171
Treatment
Phase 1 treatment study for metastatic solid tumors
A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with Inherited or Tumor Mutations
Clinicaltrials.gov identifier:
NCT04890613
Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer
Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)
Clinicaltrials.gov identifier:
NCT06380751
Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation
An Online Program to Help Asian American Breast Cancer Survivors Manage Pain and Depression
Clinicaltrials.gov identifier:
NCT06085313
Quality of Life
An online program to help Asian American breast cancer survivors manage pain and depression
Treating Advanced or Metastatic Cancers with a New PARP Inhibitor (GS-0201) Alone or Combined with Other Drugs
Clinicaltrials.gov identifier:
NCT06167317
Treatment
Treatment study for people with advanced or metastatic solid tumors
HEAL-ABC Study: Harnessing E-Mindfulness Approaches for Living-After Breast Cancer
Clinicaltrials.gov identifier:
NCT06748222
Quality of Life
Quality of life study for young breast cancer survivors who have symptoms associated with depression
Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug Combined with Olaparib
Clinicaltrials.gov identifier:
NCT06488378
Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation
Sponsored By
